Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lineage Cell Therapeutics, Inc. filings document the disclosures of a clinical-stage biotechnology company developing allogeneic cell therapies and cell transplant product candidates. The company’s reports and current-event filings cover financial results, business updates, pipeline developments, research collaborations, clinical-program milestones, and manufacturing progress involving programs such as OpRegen, OPC1, and ReSonance.
Regulatory filings also describe Lineage’s capital structure and financing activity, including common share offerings under shelf registration and at-the-market arrangements. Proxy materials cover board matters, executive compensation, equity awards, shareholder voting items, and governance disclosures, while 8-K filings record material events tied to collaborations, grant-related developments, operating results, and other corporate updates.
Lineage Cell Therapeutics, Inc. reported Q1 2026 revenue of $1.7M, up from $1.5M a year earlier, driven mainly by collaboration income. Operating expenses rose to $9.3M, leading to a net loss attributable to Lineage of $4.8M, or $(0.02) per basic share.
Cash, cash equivalents and marketable securities totaled $53.4M as of March 31, 2026, and management believes this will fund planned operations for at least twelve months. The company continues to advance its OpRegen collaboration with Roche, OPC1 spinal cord program, and preclinical pipeline, while using an at-the-market facility and prior warrant financings for capital.
Lineage Cell Therapeutics reported first quarter 2026 results showing modest revenue growth alongside higher R&D investment and continued strategic pipeline progress. Total revenue for the quarter ended March 31, 2026 was $1.7 million, up from $1.5 million a year earlier, mainly from a collaboration with William Demant Invest.
Total operating expenses rose to $9.3 million from $8.0 million, driven by increased R&D spending on OPC1, the ReSonance hearing-loss program, and other preclinical work. Net loss attributable to Lineage was $4.8 million, or $0.02 basic and $0.03 diluted per share, compared with a $4.1 million net loss in 2025.
The company ended the quarter with $53.4 million in cash, cash equivalents, and marketable securities, which it expects to fund planned operations into the second quarter of 2028. Operationally, Lineage highlighted positive three-year OpRegen data in geographic atrophy, treatment of a second chronic spinal cord injury patient with OPC1, launch of its COR1 corneal program, progress on its AlloSCOPE 5D/ILT1 manufacturing initiative, and the formation of a new Scientific Advisory Board and senior clinical leadership.
Lineage Cell Therapeutics, Inc. is asking shareholders to vote at its June 10, 2026 annual meeting on electing seven directors, ratifying Baker Tilly US, LLP as auditor for 2026, and approving on an advisory basis 2025 executive pay. Shareholders of record as of April 20, 2026, when 249,298,295 common shares were outstanding, may vote by internet, phone, mail, or in person. The proxy also details board structure, director independence, committee responsibilities, sustainability initiatives, and 2025 compensation, including a performance-based bonus program and stock option grants for directors and executives.
Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share. Following these purchases, he directly holds 255,516 common shares.
Lineage Cell Therapeutics, Inc. is registering up to $100,000,000 of securities to sell from time to time under a shelf registration. The registration covers common shares, preferred shares, debt securities and warrants, and securities issuable upon conversion or exercise, with specific terms to be provided in prospectus supplements.
The company states its common shares trade on the NYSE American and the TASE under the symbol LCTX, and reports a last NYSE American sale price of $1.77 per share on March 9, 2026. Proceeds treatment and offering mechanics will be described in each prospectus supplement; the prospectus permits sales directly, through agents, or via underwriters and contemplates at-the-market and other distribution methods.
Lineage Cell Therapeutics, Inc. filed a new prospectus supplement to support an at-the-market offering of its common shares with an aggregate offering price of up to $60,000,000 through or to B. Riley Securities, Inc. This program is under an existing Form S-3 shelf registration and sales agreement framework and excludes $22,583,663.82 in common shares already sold under prior prospectus supplements.
Ligand Pharmaceuticals, Inc. amends its prospectus supplement to increase the aggregate amount of common shares it may sell under its at-the-market sales agreement with B. Riley Securities, Inc. to $60,000,000. The supplement states this raises the ceiling for sales under the Sales Agreement dated March 22, 2024.
The supplement notes $22,583,663.82 in aggregate gross sales have been sold under the prior supplements and base prospectus to date. The filing also discloses the last reported NYSE American sale price of the common shares was $1.77 per share on March 9, 2026. The offering is subject to the Base Prospectus, prior supplements and the risk factors already disclosed.
Lineage Cell Therapeutics reported that its President and CEO, Brian M. Culley, received a grant of stock options covering 3,250,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the terms, one quarter of these options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments thereafter, contingent on continued employment. Following this award, Culley holds 3,250,000 stock options directly.